A Study Using Electronic Health Information to Learn About Rivaroxaban Compared to Warfarin in Participants With Non-valvular Atrial Fibrillation (NVAF) and Diabetes

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

116049 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-08-21

Study Completion Date

2021-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In people with type 2 diabetes, the body does not make enough of a hormone called insulin or does not use insulin well. This results in high blood sugar levels.

People with diabetes are more likely to have non-valvular atrial fibrillation (NVAF) compared to people who do not have diabetes. Having both NVAF and diabetes can increase the chances of developing other serious health conditions, like blood clots and strokes.

People with NVAF may receive treatments to help lower the risk of blood clots. This can then help to lower the risk of having a stroke. Two of these treatments are rivaroxaban and warfarin.

In this study, the researchers will look at how well rivaroxaban works and how safe it is compared to warfarin in routine clinical practice. The study will include men and women who are at least age 18 and who have NVAF and type 2 diabetes.

The researchers in this study will use the participants' health information from an electronic database.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Real-world Dosing Patterns of Rivaroxaban in the United States

NCT03242278

Atrial Fibrillation

COMPLETED

Assessment of Dapagliflozin on Vascular Health in Patients With Type 2 Diabetes

NCT05139914

Diabetes Mellitus, Type 2 Endothelial Dysfunction

RECRUITING PHASE4

Effect of Sodium Glucose Co-transporter 2 Inhibitors on Left Atrial Remodeling

NCT05993897

Atrial Fibrillation

UNKNOWN NA

Cardiovascular Outcomes in Participants With Type 2 Diabetes Mellitus (T2DM)

NCT03249506

Diabetes Mellitus, Type 2

COMPLETED

Acute Liver Injury in Patients on Dapagliflozin

NCT02695095

Acute Liver Injury

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Atrial Fibrillation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Group A

Participants with diagnoses of type 2 diabetes and non-valvular atrial fibrillation (NVAF) newly-initiated on rivaroxaban

Rivaroxaban (Xarelto, BAY59-7939)

Intervention Type DRUG

Participants receive rivaroxaban (per written prescription, medication administration or self-report of medication use)

Group B

Participants with diagnoses of type 2 diabetes and non-valvular atrial fibrillation (NVAF) newly-initiated on warfarin

Warfarin

Intervention Type DRUG

Participants receive warfarin (per written prescription, medication administration or self-report of medication use)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Rivaroxaban (Xarelto, BAY59-7939)

Participants receive rivaroxaban (per written prescription, medication administration or self-report of medication use)

Intervention Type DRUG

Warfarin

Participants receive warfarin (per written prescription, medication administration or self-report of medication use)

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Be ≥18 years of age at the time of anticoagulation initiation
* Have diagnoses of type 2 diabetes and Non-valvular atrial fibrillation (NVAF)
* Have no record of prior oral anticoagulant (OAC) use in the prior 12-months
* Newly initiated on Rivaroxaban or Warfarin (index date)
* Have ≥12-months of electronic health record (EHR) activity prior to the index date and received care documented in the EHR database from at least one provider in the 12-months prior

Exclusion Criteria

* Evidence of valvular heart disease defined as any rheumatic heart disease, mitral stenosis or mitral valve repair/replacement
* Pregnancy
* Use of rivaroxaban doses other than 15 mg once daily or 20 mg once daily or the presence of other indication(s) for OAC use
* Any prior OAC utilization per written prescription or self-report at baseline

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No